Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “bask...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Chi, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992878/
https://www.ncbi.nlm.nih.gov/pubmed/29880008
http://dx.doi.org/10.1186/s13045-018-0622-4
_version_ 1783330125826228224
author Chen, Yu
Chi, Ping
author_facet Chen, Yu
Chi, Ping
author_sort Chen, Yu
collection PubMed
description Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “basket” study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing “tumor-agnostic” targeted therapies in rare tumors.
format Online
Article
Text
id pubmed-5992878
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59928782018-07-05 Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers Chen, Yu Chi, Ping J Hematol Oncol Research Highlight Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent “basket” study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing “tumor-agnostic” targeted therapies in rare tumors. BioMed Central 2018-06-07 /pmc/articles/PMC5992878/ /pubmed/29880008 http://dx.doi.org/10.1186/s13045-018-0622-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Chen, Yu
Chi, Ping
Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_full Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_fullStr Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_full_unstemmed Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_short Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
title_sort basket trial of trk inhibitors demonstrates efficacy in trk fusion-positive cancers
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992878/
https://www.ncbi.nlm.nih.gov/pubmed/29880008
http://dx.doi.org/10.1186/s13045-018-0622-4
work_keys_str_mv AT chenyu baskettrialoftrkinhibitorsdemonstratesefficacyintrkfusionpositivecancers
AT chiping baskettrialoftrkinhibitorsdemonstratesefficacyintrkfusionpositivecancers

Ejemplares similares